IGC Pharma, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’EQUITY
| Three months ended September 30, 2025 | Number of CommonShares | CommonStock and AdditionalPaid in Capital ($) | Accumulated Deficit ($) | AccumulatedOther ComprehensiveLoss ($) | Total Stockholders’ Equity ($) |
|---|---|---|---|---|---|
| Balances as of June 30, 2025 | 84,141 | 131,920 | (122,343) | (3,499) | 6,078 |
| Common stock-based compensation & expenses, net | - | 742 | - | - | 742 |
| Common stock subscribed but not yet issued | - | - | - | - | - |
| Issuance of common stock through offering (net of expenses) | 7,818 | 3,112 | - | - | 3,112 |
| Other adjustments | - | - | - | - | - |
| Net loss | - | - | (1,821) | - | (1,821) |
| Foreign currency translation adjustments | - | - | - | (19) | (19) |
| Reclassification due to the liquidation of Subsidiaries | - | - | 1,336 | (1,336) | - |
| Balances as of September 30, 2025 | 91,959 | 135,774 | (122,828) | (4,854) | 8,092 |
| Balances as of June 30, 2026 | 102,417 | 142,065 | (130,228) | (5,705) | 6,132 |
| Common stock-based compensation & expenses, net | 4,358 | 1,030 | - | - | 1,030 |
| Common stock subscribed but not yet issued | - | (635) | - | - | (635) |
| Issuance of common stock through offering (net of expenses) | 7,575 | 2,027 | - | - | 2,027 |
| Other adjustments | - | - | - | - | - |
| Net loss | - | - | (2,046) | - | (2,046) |
| Foreign currency translation adjustments | - | - | - | (7) | (7) |
| Reclassification due to the liquidation of Subsidiaries | - | - | - | - | - |
| Balances as of September 30, 2026 | 114,350 | 144,487 | (132,274) | (5,712) | 6,501 |
| Nine months ended September 30, 2025 | Number of CommonShares | CommonStock andAdditionalPaid in Capital($) | Accumulated Deficit($) | AccumulatedOther ComprehensiveLoss ($) | Total Stockholders’ Equity ($) |
|---|---|---|---|---|---|
| Balances as of December 31, 2024 | 78,203 | 129,307 | (119,589) | (3,459) | 6,259 |
| Common stock-based compensation & expenses, net | - | 1,698 | - | - | 1,698 |
| Common stock subscribed but not yet issued | - | - | - | - | - |
| Issuance of common stock through offering (net of expenses) | 13,756 | 4,769 | - | - | 4,769 |
| Other adjustments | - | - | 43 | (43) | - |
| Net loss | - | - | (4,618) | - | (4,618) |
| Foreign currency translation adjustments | - | - | - | (16) | (16) |
| Reclassification due to the liquidation of Subsidiaries | - | - | 1,336 | (1,336) | - |
| Balances as of September 30, 2025 | 91,959 | 135,774 | (122,828) | (4,854) | 8,092 |
| Balances as of December 31, 2025 | 95,038 | 138,014 | (124,890) | (5,701) | 7,423 |
| Common stock-based compensation & expenses, net | 6,715 | 2,801 | - | - | 2,801 |
| Common stock subscribed but not yet issued | - | 255 | - | - | 255 |
| Issuance of common stock through offering (net of expenses) | 12,597 | 3,417 | - | - | 3,417 |
| Other adjustments | - | - | - | - | - |
| Net loss | - | - | (7,384) | - | (7,384) |
| Foreign currency translation adjustments | - | - | - | (11) | (11) |
| Reclassification due to the liquidation of Subsidiaries | - | - | - | - | - |
| Balances as of September 30, 2026 | 114,350 | 144,487 | (132,274) | (5,712) | 6,501 |
| September 30, 2026, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.